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Abstract
Background: Various strains of Bacillus thuringiensis (Bt) have been found to produce parasporal proteins that are 
cytotoxic to human cancer cells. This study aims to establish the binding affinity of purified Bt 18 toxin for CEM-SS (T 
lymphoblastic leukaemia cell line), to determine if competition exists between the toxin and commercial anticancer 
drugs for the binding site on CEM-SS and to localise the binding site of the toxin on CEM-SS.
Methods: In homologous competitive binding study, the purified toxin was labelled with biotin and allowed to 
compete with unlabelled toxin for binding sites on CEM-SS and its dissociation constant (Kd) was determined. 
Comparisons were made with CCRF-SB, CCRF-HSB-2 and MCF-7. In heterologous competitive binding study, 
biotinylated toxin competition was determined with two other Bt toxins (crude Btj and crude Bt 22) and anticancer 
drugs (cisplatin, doxorubicin, etoposide, navelbine and methotrexate). To localise the binding site under the confocal 
microscope, the biotinylated toxin was tagged with FITC-conjugated streptavidin.
Results: Homologous competitive binding assays revealed decreasing binding affinity of Bt 18 toxin for CEM-SS, CCRF-
SB, and CCRF-HSB-2 with Kd of 8.44 nM, 14.98 nM and 17.71 nM respectively. Kd for MCF-7 was not determined as the 
inhibitory concentration (IC50) was not reached. Heterologous competitive study showed little competition (< 30%) 
between biotinylated Bt 18 toxin and all test compounds used. Confocal microscopy revealed binding of toxin at the 
periphery of the cell.
Conclusions: It was postulated that purified Bt 18 toxin binds on the cell surface of CEM-SS and the mechanism of cell 
death may differ from that of Btj toxin, Bt 22 toxin and all five anticancer drugs used in this study, since it did not 
significantly compete with these compounds for the same binding site.
Background
Bacillus thuringiensis (Bt) is a gram positive, facultative
aerobic and spore-forming bacteria. It produces paraspo-
ral inclusions containing various insecticidal delta-endo-
toxins during its sporulative phase and has been used in
agricultural fields as an insecticide for decades [1,2].
Recently, it has been found that parasporal proteins of Bt
exhibit cytotoxic effect on human cancer cells [3-5]. In
2000, the word parasporin was first introduced by Mizuki
et al. to describe bacterial parasporal proteins capable of
discriminatively killing cancer cells [6]. To date, four
classes of parasporins have been identified, namely
parasporin 1 (PS1), parasporin 2 (PS2), parasporin 3
(PS3) and parasporin 4 (PS4) [7]. Though many studies
have been carried out to characterise these parasporins
and to investigate their mechanism of action on human
cancer cell lines, little is known about the cancer cell-kill-
ing mechanism and the receptors to which these proteins
bind on cancer cells. This is especially true for PS3 and
PS4 [7]. Previously we demonstrated that purified Bacil-
lus thuringiensis (Bt) 18 toxin, from Bt 18, a Malaysian
isolate, was selectively cytotoxic against CEM-SS but not
human T lymphocytes and was non-haemolytic [8]. We
hypothesised that the toxin binds to a specific receptor
on CEM-SS and that it competes with commercially
available anticancer drugs for the receptor. This study
was therefore conducted to further investigate the bind-
ing affinity of the toxin for CEM-SS, its interaction with
other Bt toxins and commercially available anticancer
drugs for binding sites on CEM-SS and to localise where
the toxin binds to the cells. Since leukaemia is a common
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and deadly disease, there is an urgency to develop new
and more efficient treatment methods to deal with the
problem. Purified Bt 18 toxin used in this study repre-
sents a good potential therapeutic agent as it is selectively
cytotoxic to CEM-SS, non-cytotoxic to human T lympho-
cytes and non-haemolytic. These properties of purified
Bt 18 toxin may allow it to be used as part of a combina-
tion therapy on top of current anticancer drugs, thus low-
ering the dose required for these drugs. This study shows
t h a t  p u r i f i e d  B t  1 8  t o x i n  b i n d s  o n  t h e  c e l l  s u r f a c e  o f
CEM-SS and its mechanism of cell death may differ from
that of Btj toxin, Bt 22 toxin and the selected anticancer
drugs since it did not significantly compete with these
compounds for the same binding site.
Methods
Bacillus thuringiensis culture, activation and purification
Bacillus thuringiensis was grown to induce sporulation in
conditions described by Nadarajah et al. [8]. After sporu-
lation Bt was lysed using 1 M NaCl solution and centri-
fuged at 9000 rpm for 10 mins at 4°C. The pellet was
washed once with 1 M NaCl solution, twice with dH2O
and re-suspended in Tris/KCl buffer (10 mM Tris/HCl,
10 mM KCL, pH7.5). Inclusions were separated from
spores by ultracentrifugation at 25,000 rpm, 4°C for 16
hours on a discontinuous sucrose density gradient of 67%,
72% and 79% (w/v) in Tris/KCl buffer as described by
Thomas and Ellar [9]. Paraporal inclusions were then sol-
ubilised and activated using similar methods as described
by Nadarajah et al. [8]. The supernatant containing the
activated proteins was collected after centrifugation at
13000 rpm for 5 mins at 4°C. The solubilised and acti-
vated proteins were desalted using Amicon® Ultra centri-
fuge tubes (Millipore) with PBS (pH7.4) by centrifugating
at 75000 rpm, 4°C for 15 mins. The desalted proteins
were purified by means of FPLC using Resource Q™
(Amersham Biosciences) high performance column con-
nected to AKTA™ System. The start buffer used was 20
mM piperazine and the elution buffer, 1 M NaCl. Proteins
were separated into 15 ml tubes, concentrated and
desalted with PBS (pH7.4).
Human T lymphocyte extraction
After approval by the ethics committee and informed
consent, 20 ml of blood was drawn from a healthy donor.
To each ml of whole blood, 50 μl of ResetteSep® Human T
Cell Enrichment Cocktail was added and the mixture was
incubated at room temperature for 20 mins. The sample
was diluted with equal volume of PBS, layered on top of
Ficoll-Pague™ Plus in a 15 ml tube and centrifuged for 35
mins at 5000 rpm at room temperature. The enriched T
cells found at the Ficoll-Pague™ Plus: plasma interface
were aspirated and washed twice with PBS before use.
Cell culture
Human T lymphocytes, CEM-SS (T-lymphoblastic leu-
kaemic cells), CCRF-SB (B lymphoblasts from acute
lymphoblastic leukaemic patient), CCRF-HSB-2 (T lym-
phoblasts from acute lymphoblastic leukaemic patient)
and MCF-7 (breast cancer cells) were cultured using
either RPMI 1640 medium (human T lymphocytes,
CEM-SS, CCRF-SB and CCRF-HSB-2) or DMEM
medium (MCF-7) supplemented with 10% foetal bovine
serum, 1% 100 IU/ml penicillin and 100 μg/ml streptomy-
cin, 1% sodium pyruvate and 1% HEPES solution at 37°C
in a humidified 5% CO2 atmosphere.
Determination of protein concentration and sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) analysis
Protein concentration was determined using the method
of Bradford [10]. SDA-PAGE analysis was carried out on
the solubilised and activated parasporal proteins as
described by Laemmili and Favre [11] and Thomas and
Ellar [9] using a 4% (w/v) stacking gel and 10% (w/v)
resolving gel.
Biotinylation of purified Bt 18 toxin and detection of 
biotinylated toxin
Appropriate volume (calculated using manufacturer's for-
mulae) of 10 mM solution of sulfo-NHS-LC-biotin
(Pierce) was added to purified Bt 18 toxin in 1:50 molar
ratio and was incubated at 4°C for 2 hours. Excess biotin
was removed by size exclusion using Amicon® Ultra cen-
trifugal filter device by centrifugation at 7500 rpm for 10
minutes at room temperature. The biotinylated was
detected using the HABA-avidin method. The HABA-
avidin solution was prepared by adding 60 μl of 0.01 M
HABA (4'-hydroxyazobenzene-2-carboxylix acid)
( P i e r c e )  t o  1  m g  o f  I m m u n o P u r e ® Avidin (Pierce). The
solution was then made up to 2 ml using PBS (pH7.4)
solution. The HABA-avidin solution was placed in the
negative control wells and test wells of a flat-bottom 96-
well microplate. Its absorbance was measured at 500 nm.
The decrease in absorbance in comparison with the con-
trol wells indicated the presence of biotinylated toxin.
Cell viability assays
Cytotoxic tests were performed as described in previ-
ously published literature [8]. Briefly, 50 μl of various
concentrations (0 μg/ml to 160 μg/ml) of filtered Bt toxin
or anticancer drug was added to 50 μl of exponentially
growing cell suspensions (2 × 106 cells/ml). The treated
cells were then incubated at 37°C for 72 hours. The stan-
dard MTT ((3-[4,5-dimethylthizol-2-yl]-2,5-diphenyltet-
razolium bromide) colorimetric method was applied as
described by Shier [12]. Reading of absorbance was car-
ried out at 550 nm with reference at 620 nm. The 50%Wong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:86
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inhibition concentration (IC50) values were deduced from
the dose-response curves.
Homologous competitive binding assays
Fixed concentration (7.41 nM) of biotinylated toxin and
increasing concentrations (0 nM to 59.26 nM) of unla-
belled purified Bt 18 toxin were added to CEM-SS (2 ×
106 cells/ml) in a 96-well flat bottom microplate. A nega-
tive control was also included. The plate was incubated at
37°C for 1 hour. All unbound toxins were removed by
centrifugating the microplate at 1200 rpm for 10 minutes
at room temperature and the supernatant removed.
Detection of the biotinylated purified Bt 18 toxin was by
the HABA-avidin method above. Homologous competi-
tive binding assays for other cell lines (CCRF-SB, CCRF-
HSB-2 and MCF-7) were carried out in the same manner.
The dissociation constant was calculated by determining
the IC50 (dose at which 50% displacement of the biotiny-
lated purified Bt 18 toxin occurred) and by applying the
IC50 in the modified Cheng and Prusoff equation [13].
Heterologous competitive binding assays
Heterologous competitive binding assays were carried
out for two different Bt toxins (crude Btj and crude Bt 22
toxins) and five commercially available anticancer drugs
(cisplatin, doxorubicin, etoposide, methotrexate, navel-
bine). Conditions were the same as those used in homolo-
gous competitive binding assays.
Localisation of binding site of purified Bt 18 toxin on CEM-SS
Untreated cells and cells treated with 29.63 nM of bioti-
nylated purified Bt 18 toxin at 1, 2, 12 and 24 hours were
fixed using 4% formaldehyde for 15 minutes at room tem-
perature. Upon fixative removal, cell pellets were washed
twice using Hank's balanced salt solution (HBSS), re-sus-
pended in HBSS and incubated with 1 μl of ready-to-use
fluorescein-conjugated avidin (Pierce), 5 μl of reconsti-
tuted Alexa Fluor® 594 (Invitrogen) and 2 μl of ready-to-
use Hoechst 33342 (Invitrogen) for 15 minutes at room
temperature in a dark room. The dyes were removed by
centrifugation and the cell pellets were washed twice
using HBSS solution and re-suspended in HBSS solution.
One drop of the sample (approximately 10 μl) was placed
on a microscope slide followed by one drop of ProLong
Gold antifade reagent (Invitrogen). The sample was cured
for at least 24 hours in the dark before viewing under the
confocal microscope (Carl Zeiss).
Statistical analysis
Statistical analysis was done using SPSS version 16.0. For
comparison of two means, the paired t-test was used. P
values less than or equal to 0.05 were taken as statistically
significant and values less than or equal to 0.001 were
taken as highly significant.
Results
The effect of biotinylated Bt 18 toxin and the unlabelled 
toxin on cell viability of CEM-SS
Purified Bt 18 toxin had similar effect on CEM-SS at 72
hours whether biotinylated or unlabelled (Figure 1). The
highest percentage of cell death achieved by the biotiny-
lated toxin was 45.87% (+/-2.21%) and that of the unla-
belled toxin was 40.55% (+/-5.79%). The difference was
statistically insignificant (p > 0.05).
Homologous competitive binding assays
Similar trends were observed for CEM-SS, CCRF-SB and
CCRF-HSB-2 (Figures 2a, 2b and 2c respectively) i.e., as
the concentration of the unlabelled toxin increased, the
percentage of the biotinylated purified Bt 18 toxin bound
to the cells decreased markedly. However, for MCF-7
(Figure 2d), the decrease in the percentage of the bound
biotinylated toxin was not as marked. At 59.29 nM, the
unlabelled toxin significantly decreased the percentage of
binding of biotinlylated purified Bt 18 toxin on CEM-SS,
CCRF-SB, CCRF-HSB-2 and MCF-7 to 9.75%, 33.58%,
33.75% and 72.89% respectively (p < 0.01 for first 3 cell
lines, and p < 0.05 for MCF-7). The IC50 (concentration at
which 50% of the biotinylated purified Bt 18 toxin was
displaced) were 15.85 nM, 22.39 nM and 25.12 nM for
CEM-SS, CCRF-SB and CCRF-HSB-2 respectively. MCF-
7 did not achieve the inhibitory concentration. The Kd
was calculated using derivative of the Cheng and Prusoff
equation [13]. It was found to be 8.44 nM, 14.98 nM and
17.71 nM for CEM-SS, CCRF-SB and CCRF-HSB-2
respectively. For MCF-7, the dissociation constant could
not be determined because the inhibitory concentration
was not achieved.
Heterologous competitive binding assays
Similar trends were observed for both crude Btj toxin and
crude Bt 22 toxin (Figure 3). Both graphs showed a
decreasing trend in the percentage of biotinylated puri-
fied Bt 18 toxin bound to CEM-SS with increasing toxin
concentrations. For crude Btj toxin the percentage of
bound biotinylated purified Bt 18 toxin significantly
decreased from 100% to 78% at 59.26 nM (p < 0.001). For
crude Bt 22 toxin, the percentage of bound biotinylated
purified Bt 18 toxin significantly decreased from 100% to
80.81% at 59.26 nM (p < 0.05). However, the difference
between crude Btj toxin and crude Bt 22 toxin was statis-
tically insignificant (p > 0.05).
It was observed that the graphs show a similar pattern
for all the anticancer drugs i.e., the higher the drug con-
centration, the lower the percentage of biotinylated puri-
fied Bt 18 toxin bound to CEM-SS cells (Figure 4). There
was a statistically significant but minor decrease in the
percentage of binding of the biotinylated toxin on CEM-
SS cells when competed with methotrexate (< 30%, p <Wong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:86
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0.05) and doxorubicin (< 10%, p < 0.05) with increasing
drug concentration. On the other hand, it was found that
cisplatin, etoposide and navelbine caused a greater
decrease (> 30%) in the percentage of binding of the bioti-
nylated toxin on CEM-SS with increasing drug concen-
tration. This decrease was significant for cisplatin and
etoposide (p < 0.001) but insignificant for navelbine (p >
0.05) at the highest drug concentration (59.26 nM). The
percentage of displacement of the biotinylated toxin on
CEM-SS at the highest drug concentration for the cispla-
tin, doxorubicin, etoposide, navelbine and methotrexate
were 32.76%, 9.82%, 44.67%, 40.27% and 20.40% respec-
tively. However, such high percentage of displacement of
the biotinylated toxin at the highest drug concentration
was also confounded by a high percentage of cell death
(results not shown). Therefore, displacement of the bioti-
nylated toxin at the highest drug concentration may or
may not be due to true competition.
Localisation of the binding site of purified Bt 18 toxin on 
CEM-SS
Under the confocal microscope, the cell membrane of
CEM-SS and T lymphocytes stained with Alexa Fluor®
594 appeared red while the nucleus stained with Hoechst
33342 appeared blue. On the other hand, biotinylated
purified Bt 18 toxin tagged with FITC-conjugated
streptavidin appeared green or greenish yellow (as a
result of overlap with Alexa Fluor® 594). For CEM-SS (Fig-
ure 5), biotinylated purified Bt 18 toxin appeared at all
test intervals (1, 2, 12 and 24 hours). The intensity and
extent of staining increased relatively with increased
incubation period. The biotinylated toxin was seen at the
periphery of the cell where the cell membrane was
located. For human T lymphocytes (Figure 6), biotiny-
lated purified Bt 18 toxin did not appear at all test inter-
vals except at 24 hours. Compared to CEM-SS at the
Figure 1 Cell viability assay-comparing the effect of biotinylated and unlabelled purified Bt 18 toxin on CEM-SS. Both biotinylated purified 
Bt 18 toxin and the unlabelled toxin were incubated with CEM-SS cells at 37°C for 72 hours.Wong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:86
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same interval, the intensity and extent of staining was
very much less remarkable.
Discussion
Binding studies related to Bt have largely been carried out
in insects mainly for characterisation of Bt toxins and the
determination of Bt toxin resistance in insects [14].
According to data from cell viability assays in this study,
biotinylation did not affect the biological activity of the
toxin. This phenomenon was observed in other studies
[15,16]. Results from the homologous competitive assays
suggested that purified Bt 18 toxin had a higher affinity
for CEM-SS, followed by CCRF-SB and CCRF-HSB-2 as
the dissociation constant is inversely proportional to the
binding affinity. For MCF-7, the dissociation constant
could not be obtained because the inhibitory concentra-
tion (IC50) was not achieved. This could be explained by
the fact that CEM-SS, CCRF-SB and CCRF-HSB-2 are all
leukaemic cells while MCF-7 represents a very different
class of cells, i.e. breast cancer cells. While the first three
types may all express specific binding sites for purified Bt
18 toxin, MCF-7, being a totally different class of cells,
may not exhibit similar binding sites for the toxin. Since
comparisons had already been made between CEM-SS
and two other leukaemic cell lines (CCRF-SB and CCRF-
HSB-2), MCF-7 was used in this case to demonstrate that
a different class of cell line may show lower affinity for the
purified toxin. When compared to experiments per-
formed previously, the binding results agreed well with
the cell viability assays. Purified Bt18 toxin exhibits cyto-
toxocity towards CEM-SS cells whereas MCF-7 cells are
relatively unharmed [17]. The lower cytotoxicity of the
toxin for MCF-7 cells may be explained by the lower
affinity the toxin has for these cells.
The scarcity of literature for the binding mechanisms of
parasporin makes comparison of binding affinity of puri-
fied Bt 18 toxin on CEM-SS with other Bt parasporal pro-
teins and cancer cell types difficult. However, from
Figure 2 Homologous competitive binding assays. The unlabelled toxin and biotinylated purified Bt 18 toxin were allowed to compete for binding 
site on A) CEM-SS, B) CCRF-SB, C) CCRF-HSB-2 and D) MCF-7 separately using fixed concentration (7.41 nM) of biotinylated purified Bt 18 toxin and 
various concentrations (0 nM to 59.26 nM) of the unlabelled toxin for 1 hour at 37°C.Wong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:86
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binding experiments done on insects, it was found that
the dissociation constants of various Bt toxins for insect
c e l l s  w e r e  h i gh e r  t h a n  t h a t  o f  p u ri f i ed  B t  1 8  t o x i n  f o r
CEM-SS cells. As the dissociation constant is inversely
proportional to the binding affinity, this implies that
binding affinity of purified Bt 18 toxin for CEM-SS cells
was relatively higher than that of other Bt toxins for
insect cells [18,19]. This finding is interesting as it may
mean that the weak cytotoxicity of purified Bt 18 toxin on
leukaemic cells could be influenced by factors other than
its binding affinity for the cell line since the binding affin-
ity was found to be relatively higher in comparison with
insect studies.
Heterologous competitive binding assays suggested
that there was a minor degree of competition between
biotinylated Bt 18 toxin and crude Btj toxin as well as
crude Bt 22 toxin as the percentage of bound biotinylated
toxin was significantly decreased to 78% (p < 0.001) and
80.81% (p < 0.05) at 59.26 nM respectively. This low
degree of competition might or might not represent true
competition among toxins because it was also observed
that at such concentration, there was a significant cell
death of 10.66% (p < 0.05) and 2.65% (p < 0.05) for crude
Btj toxin and crude Bt 22 toxin respectively (results not
shown). The decrease in the percentage of the bound
biotinylated toxin might be confounded by cell death that
occurred at the same time. Besides, it may also be con-
founded by the possibility of non-specific binding sites.
H o w e v e r ,  e v e n  i f  t r u e  c o m p e t i t i o n  w e r e  t o  o c c u r ,  t h e
degree of competition was small as only approximately
20% displacement of the biotinylated toxin occurred for
both crude Btj toxin and crude Bt 22 toxin. Little or no
competition between biotinylated purified Bt 18 toxin
and crude Btj toxin further supported earlier results by
Nadarajah et al., as purified Bt 18 toxin was non-haemo-
lytic and non-cytotoxic to normal human T lymphocytes
while crude Btj toxin was both haemolytic and cytotoxic
to normal human T lymphocytes [8].
Figure 3 Heterologous competitive binding assays- biotinylated purified Bt 18 toxin versus crude Btj and crude Bt 22 toxins. Fixed concen-
tration (7.41 nM) of biotinylated purified Bt 18 toxin was allowed to compete with various concentrations (0 nM to 59.26 nM) of crude Btj toxin and 
crude Bt 22 toxin separately for 1 hour at 37°C using CEM-SS cell line.Wong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:86
http://www.jeccr.com/content/29/1/86
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Heterologous competitive binding assays using antican-
cer drugs showed that there was a decrease in the per-
centage of bound biotinylated purified Bt 18 toxin in cell
population treated with the anticancer drugs at 59.26 nM
(32.76%, 9.82%, 44.67%, 40.27%, 20.40% for cisplatin, dox-
orubicin, etoposide, navelbine and methotrexate respec-
tively). The selected anticancer drugs in this study bind to
and enter cancer cells via various mechanisms and target
various sites in these cells. For instance, methotrexate is
an antimetabolite and a potent inhibitor of the enzyme
dihydrofolate reductase (DHFR) which blocks DNA syn-
thesis and stops cell replication [20]. Navelbine is a vinca
alkaloid which binds to tubulin and causes inhibition of
the assembly of the mitotic spindles, arresting cells in
metaphase and induces apoptosis [21]. Both doxorubicin
and etoposide exert their cytotoxic effect by forming a
complex with DNA and topoisomerase II, leading to
breaks in double-stranded DNA [20,22]. On the other
hand, cisplatin works by binding to DNA via intrastrand
and interstrand crosslinks. This leads to inhibition of
DNA replication and transcription, resulting in breaks
and miscoding and eventually apoptosis [20]. By compet-
ing purified Bt 18 toxin with each anticancer drug sepa-
rately, it allows one to study the mechanism of action of
purified Bt 18 toxin by comparing with that of the anti-
cancer drug. If the drugs and the toxin showed competi-
tion then there is a possibility of these drugs either
interfering with toxin binding to CEM-SS cells or the
toxin and the drugs sharing a common binding site on the
cell membrane which initiates a sequence of events lead-
ing to cell death. All results for the competitive binding
were statistically significant (p < 0.05) except for navel-
bine (p > 0.05). However, two confounding factors need
to be taken into consideration. Firstly, these findings were
c o n f o u n d e d  b y  a  s i g n i f i c a n t l y  h i g h  p e r c e n t a g e  o f  c e l l
death at such high drug concentration (59.26 nM)
(21.98%, 11.72%, 22.95%, 22.10%, and 10.92% for cispla-
tin, doxorubicin, etoposide, navelbine and methotrexate
Figure 4 Heterologous competitive binding assays- biotinylated purified Bt 18 toxin versus various anticancer drugs. Fixed concentration 
(7.41 nM) of biotinylated purified Bt 18 toxin was allowed to compete with various concentrations (0 nM to 59.26 nM) of cisplatin, doxorubicin, etopo-
side, methotrexate and navelbine, separately for 1 hour at 37°C.Wong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:86
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Figure 5 Confocal microscopic appearance of biotinylated purified Bt 18 toxin-treated CEM-SS. CEM-SS cells were treated with fixed concen-
tration of biotinylated purified Bt 18 toxin at various time intervals. The biotinylated toxin was then tagged with FITC-conjugated streptavidin (green). 
The biotinylated toxin was found at the periphery of treated CEM-SS cells. Increased binding of the biotinylated toxin was observed with increased 
incubation period. (A) Untreated negative control at 24 hours. (B) to (E) Treated cells at 1, 2, 12 and 24 hours respectively. Magnification: 630×. B = 
Biotinylated purified Bt 18 toxin, M = Cell membrane, N = Nucleus. Bar = 10 μm.Wong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:86
http://www.jeccr.com/content/29/1/86
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Figure 6 Confocal microscopic appearance of biotinylated purified Bt 18 toxin-treated human T lymphocytes. Human T lymphocytes were 
treated with fixed concentration of biotinylated purified Bt 18 toxin at various time intervals. The biotinylated toxin was then tagged with FITC-conju-
gated streptavidin (green). Biotinylated toxin was not found at all intervals except 24 hours, where the binding was very minimal. (A) Untreated neg-
ative control at 24 hours. (B) to (E) Treated cells at 1, 2, 12 and 24 hours respectively. Magnification: 630 ×. B = Biotinylated purified Bt 18 toxin, M = Cell 
membrane, N = Nucleus. Bar = 10 μm.Wong et al. Journal of Experimental & Clinical Cancer Research 2010, 29:86
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respectively, p < 0.001). Next, there was a possibility of
competition for non-specific binding sites on CEM-SS
cells. Due to these confounding factors, it was difficult to
infer from the results obtained whether the decrease in
the percentage of bound biotinylated purified Bt 18 toxin
was due to true competition or confounders. However,
what could be deduced from the results was that at lower
drug concentrations, there was little competition occur-
ring between the toxin and all 5 drugs tested as the per-
centage of displacement of the biotinylated toxin was
small (< 30%), which suggested that the binding sites
(hence mechanism of action) might differ for purified Bt
18 toxin and the commercially available anticancer drugs
chosen in this study. Although there was little competi-
tion between purified Bt 18 toxin and all the five antican-
cer drugs tested, the heterologous competitive binding
assays can be a useful screening tool for drug-toxin inter-
action and for those drugs that do not compete with puri-
fied Bt 18 toxin for binding sites on CEM-SS cells, it may
be useful to test for drug synergism in future studies.
Confocal microscopy showed that purified Bt 18 toxin
bound to the periphery of CEM-SS cells, suggesting that
the binding site could be a cell surface receptor. This find-
ing coincided with immunofluorescent findings of Kitada
et al. in a study of the cytocidal action of parasporin-2 on
cancer cells [23]. It was found that parasporin-2 was dis-
tributed at the cell periphery and the immunostaining
pattern was the same as the native distribution of cad-
herin, a cell-cell adhesion protein in the plasma mem-
brane [23]. In addition, increased binding of the
biotinylated toxin on CEM-SS cells was observed when
the incubation period was increased. The extent of bind-
ing was seen to be most remarkable at 24 hours. On the
other hand, no biotinylated purified Bt 18 toxin was
detected at all test intervals in human T lymphocytes
except at 24 hours. Even at 24 hours, the extent of binding
on human T lymphocytes was minimal or much less
remarkable when compared to CEM-SS cells. Such weak
or minimal binding of the purified toxin on human T
lymphocytes coincided with the fact that purified Bt 18
toxin did not exert cytotoxic activity on human T lym-
phocytes.
Conclusions
In conclusion, purified Bt 18 toxin binds to the periphery
of CEM-SS, suggesting that the toxin most likely binds to
a cell surface receptor, which is specific to the toxin. It is
most likely that purified Bt 18 toxin binds to binding sites
that differ from crude Btj toxin or crude Bt 22 toxin.
Although confounding factors and limitations were pres-
ent at high concentrations, at low concentrations of anti-
cancer drugs, there was little competition between
purified Bt 18 toxin and the drugs used in this study, sug-
gesting that purified Bt 18 toxin most likely binds to dif-
ferent binding sites on CEM-SS when compared to the
anticancer drugs. Hence, the mechanism of action of
purified Bt 18 toxin may differ from that of the anticancer
drugs used in this study. Such data prompts us to carry
out further investigations, such as drug synergism
between purified Bt 18 toxin and commercially available
anticancer drugs and in vivo studies.
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